At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
MK0518 (Raltegravir) +2 moredrug
Likely dose
MK0518 (Raltegravir) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen
In Brief
A Phase 1 clinical trial evaluating MK0518 (Raltegravir), famotidine, and 1 other intervention for HIV-1 Infection and HIV Infections. Completed, enrolled 18 participants.
Detailed Summary
An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection, HIV Infections
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
Primary CompletionMar 2009
First PostedOct 2009
TodayJul 2026
First PostedOct 23, 2009
Enrollment StartJun 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.7 years ago
Interventions
MK0518 (Raltegravir)drug
400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
famotidinedrug
Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
omeprazoledrug
20 mg oral tablet of omeprazole, once daily for 5 days